Trafalgar International ends Q3 with $111 in cash
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Trafalgar International, Inc. (TRFA) reported no revenue in the third quarter or first nine months of 2026. It recorded a $90,335 third-quarter net loss, versus a $36,099 loss a year earlier, and $487,667 net income for the first nine months, compared with a $669,369 loss in 2025. The nine-month profit included a $621,450 gain from debt cancellation and a $1,483 gain from cancellation of Series A preferred stock; the company said these cancellations generated no operating cash inflow and the gains were nonrecurring.
Cash was $111 at September 30, 2026, while operating activities used $96,828 in cash over nine months. Total liabilities were $102,574, down from $742,464 at December 31, 2025, after historical obligations were canceled. Management said substantial doubt about the company’s ability to continue as a going concern remains for one year after issuance and that it expects to require additional financing. Management also concluded disclosure controls were ineffective as of September 30, 2026, citing material weaknesses that include limited financial-reporting resources and insufficient segregation of duties; remediation was not complete.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointTotal liabilities fell to $102,574 from $742,464 at December 31, 2025.
Negative
- Major pointGoing-concern doubt remains for the one-year period after issuance.
- Major pointDisclosure controls were ineffective as of September 30, 2026, due to material weaknesses.
- Major pointCash was $111 at September 30, 2026, with $96,828 operating cash used.
Key Figures
Key Terms
substantial doubt financial
material weaknesses financial
debt extinguishments financial
valuation allowance financial
fully diluted basis financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did TRFA report net income for the first nine months of 2026?
How much cash did TRFA have at September 30, 2026?
What drove TRFA’s higher third-quarter operating expenses?
What preferred-stock rights changed for TRFA after September 30, 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For
the quarterly period ended
For the transition period from ______________ to ______________
Commission
File Number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
(Issuer’s telephone number, including area code)
Not applicable
(Former name or former address if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
State
the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:
TABLE OF CONTENTS
| Page | ||
| PART I | FINANCIAL INFORMATION | |
| Item 1 | Financial Statements | F-2 |
| Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operation | 1 |
| Item 3 | Quantitative and Qualitative Disclosures About Market Risk | 6 |
| Item 4 | Controls and Procedures | 6 |
| PART II | OTHER INFORMATION | |
| Item 1 | Legal Proceedings | 8 |
| Item 1A | Risk Factors | 8 |
| Item 2 | Unregistered Sales of equity Securities and Use of Proceeds | 8 |
| Item 3 | Defaults Upon Senior Securities | 8 |
| Item 4 | Mine Safety Disclosures | 8 |
| Item 5 | Other Information | 8 |
| Item 6 | Exhibits | 8 |
| i |
Cautionary Note Regarding Forward Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, without limitation, statements concerning Trafalgar International, Inc.’s (the “Company”) business strategy, future operations, financial condition, anticipated financing requirements, prospective business opportunities, development and commercialization of intellectual property, licensing arrangements, anticipated operating expenses, capital requirements, corporate restructuring activities, and other matters that are not historical facts. Forward-looking statements may be identified by words and expressions such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and similar expressions, including the negatives of these terms. The absence of these words does not necessarily mean that a statement is not forward-looking. These statements reflect management’s current expectations, estimates, assumptions, and projections regarding future events and circumstances. Forward-looking statements are inherently subject to significant business, economic, regulatory, financial, operational, and other risks and uncertainties, many of which are beyond the Company’s control. Actual results, developments, and events may differ materially from those expressed or implied by such statements.
Factors that could cause actual results to differ materially from those contemplated by forward-looking statements include, but are not limited to, the following:
| ● | Limited operating history under current management. The Company has recently undergone significant changes in ownership, management, corporate governance, and strategic direction. Its ability to implement its business strategy and establish sustainable operations under its current management structure remains uncertain. |
| ● | Limited liquidity and additional financing requirements. The Company has historically experienced operating losses and limited cash resources and may require substantial additional capital to maintain its operations, satisfy its obligations, support the development of its intellectual property, and pursue its business objectives. There can be no assurance that financing will be available when required or on commercially acceptable terms. |
| ● | Intellectual property and licensing arrangements. The Company’s business interests include cannabinoid-related intellectual property, technology rights, and associated licensing arrangements. The Company’s ability to preserve, enforce, develop, commercialize, or otherwise realize economic benefits from these rights may be affected by contractual obligations, intellectual property protections, third-party performance, regulatory developments, financing availability, and market conditions. |
| ● | Research, development, and regulatory uncertainty. The development and commercialization of cannabinoid-related therapeutic technologies may involve substantial research expenditures, clinical development requirements, regulatory approvals, and extended commercialization timelines. The Company cannot assure that any existing or proposed development program will achieve its intended objectives or obtain necessary approvals. |
| ● | Dependence on third parties. The Company may depend upon licensors, licensees, research institutions, development partners, consultants, service providers, and other third parties to maintain or advance certain business activities. The failure of any such party to perform its obligations could materially adversely affect the Company. |
| ● | Changes in corporate ownership and control. The Company has undergone significant changes in controlling ownership and management. Its future operations and strategic direction may be influenced by the decisions of its controlling shareholder and Board of Directors, and the interests of controlling shareholders may differ from those of minority shareholders. |
| ● | Capitalization and potential dilution. The Company has issued multiple classes of equity securities with differing voting, conversion, and other rights. Changes to its capital structure, future equity issuances, conversions, financing transactions, or amendments to the rights of outstanding securities may affect existing shareholders’ ownership percentages, voting interests, and economic rights. |
| ii |
| ● | Debt settlements and historical obligations. The Company has entered into transactions involving the compromise, cancellation, or restructuring of certain historical obligations. Disputes concerning the interpretation, enforceability, accounting treatment, or performance of these arrangements, or the identification of additional obligations, could adversely affect its financial condition and operations. |
| ● | Ability to identify and execute business opportunities. The Company may evaluate strategic transactions, acquisitions, investments, licensing arrangements, or other business opportunities. There can be no assurance that any such transaction will be completed, that necessary financing or approvals will be obtained, or that completed transactions will achieve anticipated results. |
| ● | Internal control and disclosure compliance. The Company’s limited personnel and financial resources, historical accounting practices, and changes in management may affect its ability to maintain effective disclosure controls and procedures and internal control over financial reporting. Deficiencies in these controls could adversely affect the accuracy and timeliness of its financial reporting. |
| ● | Regulatory and legal developments. The Company may be affected by changes in federal, state, and international laws and regulations governing securities, corporate governance, intellectual property, cannabis-derived products, pharmaceutical development, taxation, and other matters relevant to its business. |
| ● | Dependence on management and key personnel. The Company’s future performance may depend substantially upon the efforts, experience, relationships, and continued services of its executive officers, directors, consultants, and other key personnel. |
| ● | Market and economic conditions. Changes in economic conditions, capital markets, investor sentiment, interest rates, inflation, and the availability of financing may adversely affect the Company’s ability to implement its business plans and obtain necessary capital. |
| ● | Trading market and liquidity risks. The Company’s common stock is quoted in the over-the-counter market and may experience limited trading activity, substantial price volatility, and limited liquidity. These conditions may impair shareholders’ ability to sell their shares and may restrict the Company’s access to equity financing. |
The foregoing factors are not exhaustive. Additional risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission, could cause actual results to differ materially from those anticipated in forward-looking statements.
Forward-looking statements speak only as of the date on which they are made. Readers should not place undue reliance on such statements. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect subsequent events, circumstances, or changes in expectations.
The Company cannot provide assurance that any anticipated development, transaction, financing, business initiative, or other future event will occur or, if it occurs, that it will produce the results currently anticipated.
As used in this Quarterly Report, unless the context otherwise requires, the terms “Trafalgar,” the “Company,” “we,” “us,” and “our” refer to Trafalgar International, Inc., and, where applicable, its consolidated subsidiaries.
| iii |
TRAFALGAR INTERNATIONAL, INC.
SEPTEMBER 30, 2026
FORM 10-Q
INDEX
| Page | |
| PART I- FINANCIAL INFORMATION | |
| ITEM 1. Financial Statements | F-2 |
| Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 | F-2 |
| Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) | F-3 |
| Consolidated Statements of Stockholders’ Deficiency for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) | F-5 |
| Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (Unaudited) | F-7 |
| Notes to Consolidated Financial Statements (Unaudited) | F-8 |
| F-1 |
PART I- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
TRAFALGAR INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
September 30, 2026 (unaudited) and December 31, 2025
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | $ | ||||||
| Total current assets | ||||||||
| OTHER ASSETS | ||||||||
| Right of first refusal agreement cost (less accumulated amortization of $ | - | - | ||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIENCY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued officers’ compensation | - | |||||||
| Loans payable to related parties | ||||||||
| Total current liabilities and total liabilities | ||||||||
| STOCKHOLDERS’ (DEFICIENCY) | ||||||||
| Preferred stock; Series A Convertible Preferred- | ||||||||
| Series B Convertible Preferred shares: | ||||||||
| Preferred shares value | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ (deficiency) | ( | ) | ( | ) | ||||
| Total liabilities and stockholders’ (deficiency) | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
| F-2 |
TRAFALGAR INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended September 30, 2026 and 2025 (Unaudited)
| September 30, 2026 | September 30, 2025 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Revenue: | ||||||||
| Product sales | $ | - | $ | - | ||||
| Consulting fees | - | - | ||||||
| Total revenue | - | - | ||||||
| Cost of product sales | - | - | ||||||
| Gross profit (loss) | - | - | ||||||
| Operating Expenses: | ||||||||
| Stock-based compensation | ||||||||
| Officers compensation | - | |||||||
| Amortization of Right of First Refusal Agreement cost | ||||||||
| Professional services | - | |||||||
| Other operating expenses | ||||||||
| Total operating expenses | ||||||||
| Income (loss) from operations | ( | ) | ( | ) | ||||
| Other income (expenses): | ||||||||
| Gain on cancellation of debt | ||||||||
| Gain on cancellation of preferred stock A | ||||||||
| Note default penalties and interest | ||||||||
| Loss on conversion of notes payable | ||||||||
| Interest expense | - | |||||||
| Total other income (expenses) | - | |||||||
| Income (loss) before provision for income taxes | ( | ) | ( | ) | ||||
| Provision for income taxes | - | - | ||||||
| Net income (loss) | $ | ( | ) | $ | ( | ) | ||
| Basic and diluted income (loss) per common share | $ | ( | ) | $ | ( | ) | ||
| Weighted average common shares outstanding-basic and diluted | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
| F-3 |
TRAFALGAR INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Nine months ended September 30, 2026 and 2025 (Unaudited)
| September 30, 2026 | September 30, 2025 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Revenue: | ||||||||
| Product sales | $ | - | $ | - | ||||
| Consulting fees | - | - | ||||||
| Total revenue | - | - | ||||||
| Cost of product sales | - | - | ||||||
| Gross profit (loss) | - | - | ||||||
| Operating Expenses: | ||||||||
| Officers compensation | ||||||||
| Stock-based compensation | - | |||||||
| Amortization of Right of First Refusal Agreement cost | - | |||||||
| Professional services | - | |||||||
| Other operating expenses | ||||||||
| Total operating expenses | ||||||||
| Income (loss) from operations | ( | ) | ( | ) | ||||
| Other income (expenses): | ||||||||
| Gain on cancellation of debt | - | |||||||
| Gain on cancellation of preferred stock A | - | |||||||
| Interest expense | - | ( | ) | |||||
| Note default penalties and interest | - | ( | ) | |||||
| Loss on conversion of notes payable | - | ( | ) | |||||
| Total other income (expenses) | ( | ) | ||||||
| Income (loss) before provision for income taxes | ( | ) | ||||||
| Provision for income taxes | - | - | ||||||
| Net income (loss) | $ | $ | ( | ) | ||||
| Basic and diluted income (loss) per common share | $ | $ | ( | ) | ||||
| Weighted average common shares outstanding-basic and diluted | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
| F-4 |
TRAFALGAR INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY
For the Three and Nine Months Ended September 30, 2026 and 2025
Unaudited
| For the nine months ended | Shares | Amount | Shares | Amount | Capital | Deficit | Total | |||||||||||||||||||||
Series A | Additional | |||||||||||||||||||||||||||
| Preferred stock | Common Stock | Paid in | Accumulated | |||||||||||||||||||||||||
| For the nine months ended | Shares | Amount | Shares | Amount | Capital | Deficit | Total | |||||||||||||||||||||
| September 30, 2025: | ||||||||||||||||||||||||||||
| Balances at December 31, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Cancellation of preferred stock A | - | |||||||||||||||||||||||||||
| Issuance of preferred stock A | - | |||||||||||||||||||||||||||
| Issuance of | - | - | - | |||||||||||||||||||||||||
| Issuance of | - | - | - | - | ||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2025 RESTATED-Note-K | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances at March 31, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Issuance of | - | - | - | |||||||||||||||||||||||||
| Issuance of common stock for notes payable conversion | ||||||||||||||||||||||||||||
| Issuance of | - | - | - | |||||||||||||||||||||||||
| Issuance of common stock for accrued compensation | ||||||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2025 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances at June 30, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Net loss for the three months ended September 30, 2025 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances at September 30, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
The accompanying notes are an integral part of these financial statements.
| F-5 |
TRAFALGAR INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY
Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)
| No. of shares | Amount | No. of shares | Amount | No. of shares | Amount | Paid in capital | Retained earnings | shareholders’ equity | ||||||||||||||||||||||||||||
Series A Preferred Stock | Series B Preferred Stock | Common stock | Additional | Total | ||||||||||||||||||||||||||||||||
| No. of shares | Amount | No. of shares | Amount | No. of shares | Amount | Paid in capital | Retained earnings | shareholders’ equity | ||||||||||||||||||||||||||||
| Balance as of December 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2026 | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance as of March 31, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Cancellation of preferred stock A | ( | ) | ( | ) | - | - | - | - | - | - | ( | ) | ||||||||||||||||||||||||
| Issuance of preferred stock A | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Issuance of | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||
| accrued compensation | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Issuance of common stock for accrued compensation | ||||||||||||||||||||||||||||||||||||
| Net income for the three months ended June 30, 2026 | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
| Balance as of June 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Net loss for the three months ended September 30, 2026 | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance as of September 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
The accompanying notes are an integral part of these financial statement
| F-6 |
TRAFALGAR INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine months ended September 30, 2026 and 2025 (Unaudited)
| September 30, 2026 | September 30, 2025 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| OPERATING ACTIVITIES | ||||||||
| Net income (loss) | $ | $ | ( | ) | ||||
| Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities: | ||||||||
| Amortization of Right of First Refusal Agreement cost | - | |||||||
| Issuance of common stock for compensation | - | |||||||
| Issuance of common stock for accrued compensation | ||||||||
| Loss on conversion of notes | - | |||||||
| Note default penalties and interest | - | |||||||
| Gain on cancellation of debt | ( | ) | - | |||||
| Gain on cancellation of preferred stock A | ( | ) | - | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts payable | ||||||||
| Accrued interest | - | |||||||
| Accrued officers’ compensation | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| INVESTING ACTIVITIES | ||||||||
| Net cash used in investing activities | - | - | ||||||
| FINANCING ACTIVITIES | ||||||||
| Proceeds from notes payable to related party | - | |||||||
| Net cash provided by financing activities | - | |||||||
| NET (DECREASE) IN CASH | ( | ) | ( | ) | ||||
| CASH BALANCE, BEGINNING OF PERIOD | ||||||||
| CASH BALANCE, END OF PERIOD | $ | $ | ||||||
| Supplemental Disclosures of Cash Flow Information: | ||||||||
| Interest paid | $ | - | $ | - | ||||
| Income tax paid | $ | - | $ | - | ||||
The accompanying notes are an integral part of these consolidated financial statements
| F-7 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
Trafalgar International, Inc., formerly known as The Greater Cannabis Company, Inc. (the “Company” or “Trafalgar”), is a Florida corporation. The Company’s predecessor was originally organized in March 2014 as The Greater Cannabis Company, LLC and was a wholly owned subsidiary of Sylios Corp. (“Sylios”) until March 10, 2017.
On
July 31, 2018, the Company completed a share exchange transaction pursuant to which it acquired all of the issued and outstanding Class
A common shares of Green C Corporation (“Green C”), an Ontario, Canada corporation incorporated on December 21, 2017, in
exchange for
Following
the Exchange, the former shareholders of Green C and their designees held approximately
The Exchange resulted in a change in the Company’s principal business activities. Beginning in 2018, the Company focused on the development, licensing, and commercialization of cannabinoid-related therapeutic technologies and drug delivery systems.
Intellectual Property and Technology Development
Through Green C and subsequent business arrangements, the Company pursued intellectual property and licensing opportunities involving the delivery and therapeutic application of cannabinoids. Green C previously held an exclusive worldwide license relating to an eluting transmucosal patch platform for noninvasive drug delivery in the cannabis field pursuant to a June 21, 2018 agreement with Pharmedica Ltd. The technology was intended to facilitate the absorption of active compounds through the oral mucosa. Between 2018 and approximately mid-2021, the Company concentrated on the commercialization of cannabinoid delivery technologies, including transmucosal and transdermal applications. Although the Company introduced an initial product and received limited commercial orders, management subsequently redirected its development efforts toward other therapeutic applications and licensing opportunities. The Company continues to hold interests in cannabinoid-related intellectual property and associated licensing rights. The Company’s ability to derive future economic benefits from these interests depends upon the enforceability and continuation of the applicable agreements, availability of development funding, performance of third-party collaborators, successful research and development activities, and applicable regulatory requirements.
Shaare Zedek Licensing and Development Arrangements
On
October 19, 2021, the Company entered into a licensing agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology
transfer organization associated with Shaare Zedek Medical Center in Jerusalem, Israel. The agreement relates to cannabinoid-based therapeutic
technology intended for potential applications involving certain neurological and neuropsychiatric conditions, including autism spectrum
disorder, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and related disorders. In connection with the licensing
arrangement, the Company also entered into a research and development arrangement involving continued development of the licensed technology
and associated clinical research activities. Under the reported terms of the licensing agreement, annual licensing payments begin at
$
| F-8 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
The
agreement further provides for royalties based upon specified levels of net sales of dietary supplement and pharmaceutical products,
together with a sublicense royalty of
Historical Capital Restructuring
Effective
October 16, 2025, the Company implemented a
On
July 29, 2026, the Company’s Board of Directors approved, and the Company filed with the Florida Department of State, Articles
of Amendment to its Articles of Incorporation to (i) change the Company’s name from The Greater Cannabis Company, Inc. to Trafalgar
International, Inc. and (ii) effect a
All common share amounts, common stock and additional paid-in capital amounts, weighted average shares outstanding, and per share amounts in the accompanying consolidated financial statements and these notes have been retroactively adjusted to reflect the Second Reverse Split for all periods presented, except where otherwise indicated.
The
Company also established a class of Series B Convertible Preferred Stock consisting of
The Company’s outstanding preferred securities have historically included Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, each governed by the applicable certificate of designation and amendments thereto. The historical conversion and voting provisions of these securities, together with subsequent transfers, cancellations, issuances, and the amendment and restatement of the Company’s Articles of Incorporation following September 30, 2026, are addressed in the accompanying notes concerning stockholders’ equity and subsequent events.
| F-9 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
June 2026 Change of Control and Corporate Reorganization
On June 29, 2026, Trafalgar Asset Management, LLC entered into transactions pursuant to which it acquired the Company’s outstanding Series A Preferred Stock and Series B Preferred Stock from the prior holders. These transactions resulted in a significant change in the Company’s ownership and governance structure. Trafalgar Asset Management, LLC became the holder of the outstanding preferred securities and acquired the rights associated with those securities under their governing instruments, subject to the terms and limitations of the applicable certificates of designation. The Company’s historical Series A Preferred Stock carried voting and conversion rights, while the Series B Preferred Stock was designed to provide significant voting control. The precise voting rights applicable following the June 2026 transfers depend upon the governing instruments and the effect of their transfer provisions. In connection with the change of control, the Company also entered into debt cancellation and release agreements with certain creditors pursuant to which specified historical indebtedness was compromised, settled, canceled, or otherwise extinguished. The financial effects of these transactions, including the recognition of any gains, equity adjustments, or related-party accounting consequences, are reflected in the accompanying consolidated financial statements to the extent required by generally accepted accounting principles in the United States (“U.S. GAAP”). Following the change of control, the Company implemented changes to its executive management and Board of Directors. On July 29, 2026, the Board of Directors appointed Carlos Septién Michel as Chief Operating Officer, Michelle Cervantes Vivanco as Chief Financial Officer, and Ernesto Gómez Berjón as Chief Growth Officer, and appointed each of them to the Board of Directors. Effective September 18, 2026, Mr. Septién was appointed Chief Executive Officer and resigned as Chief Operating Officer, and Porfirio Sanchez Talavera resigned as Chief Executive Officer. As of September 30, 2026, the Company’s management and governance structure included Porfirio Sanchez Talavera as Chairman of the Board of Directors, Carlos Septién Michel as Chief Executive Officer, Michelle Cervantes Vivanco as Chief Financial Officer, and Ernesto Gómez Berjón as Chief Growth Officer. The Company’s Board of Directors included Porfirio Sanchez Talavera, Carlos Septién Michel, Michelle Cervantes Vivanco, and Ernesto Gómez Berjón.
Business Strategy
Following the June 2026 change of control, management began evaluating the Company’s existing business interests, capital structure, historical obligations, and potential strategic opportunities.
The Company continues to maintain its interests in cannabinoid-related intellectual property and licensing arrangements while evaluating opportunities to develop, commercialize, restructure, or otherwise realize value from its existing assets and pursue additional business activities. The Company’s ability to implement its business strategy will depend upon, among other matters, its financial resources, contractual obligations, access to additional capital, applicable regulatory requirements, and the successful execution of any future transactions.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Trafalgar International, Inc. and its wholly owned subsidiary, Biocanrx, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.
Basis of Presentation and Interim Financial Statements
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”), including the requirements of Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all of the information and disclosures required by U.S. GAAP for complete annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the year ended December 31, 2025. In the opinion of management, the accompanying financial statements include all adjustments necessary to present fairly, in all material respects, the Company’s consolidated financial position as of September 30, 2026, and its consolidated results of operations, changes in stockholders’ equity (deficiency), and cash flows for the periods presented. Such adjustments consist of normal recurring adjustments and any other adjustments required for a fair presentation of the interim financial statements. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the full fiscal year ending December 31, 2026.
| F-10 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents are carried at amounts that approximate fair value because of their short-term nature. Cash balances may be maintained at financial institutions and may, from time to time, exceed applicable deposit insurance limits.
Accounts Receivable and Credit Losses
The Company recognizes trade and other receivables at the amounts expected to be collected, net of an allowance for expected credit losses, when applicable. The Company evaluates expected credit losses in accordance with Accounting Standards Codification (“ASC”) Topic 326, Financial Instruments—Credit Losses. The evaluation considers relevant historical collection experience, current conditions, and reasonable and supportable forecasts affecting the collectibility of financial assets within the scope of the standard. Receivables determined to be uncollectible are written off against the applicable allowance. Recoveries of amounts previously written off are recognized when received or otherwise realized.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions affecting the amounts reported in the financial statements and accompanying disclosures. Significant estimates and judgments may include the valuation and recoverability of intangible assets and contractual rights, recognition and measurement of liabilities, accounting for debt extinguishments and settlements, valuation of equity instruments, assessment of embedded conversion features and derivative instruments, income taxes, and the evaluation of contingencies. Management evaluates its estimates using information available as of the financial statement reporting date. Actual results could differ materially from those estimates.
Fair Value of Financial Instruments
The Company applies ASC Topic 820, Fair Value Measurement, when measuring the fair value of financial assets, financial liabilities, and other items for which fair value measurement is required or permitted under U.S. GAAP. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level hierarchy for the inputs used in valuation techniques:
| ● | Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. |
| ● | Level 2: Observable inputs other than Level 1 quoted prices, including quoted prices for similar assets or liabilities and other market-corroborated inputs. |
| ● | Level 3: Significant unobservable inputs reflecting assumptions that market participants would use in pricing the asset or liability. |
The Company uses valuation techniques appropriate to the circumstances and for which sufficient information is available, maximizing observable inputs and minimizing unobservable inputs. The carrying amounts of certain short-term financial instruments, including cash, accounts payable, accrued expenses, and certain short-term borrowings, may approximate their fair values because of their relatively short maturities. Financial instruments with significant conversion, settlement, or other contractual features are evaluated separately under the applicable accounting guidance.
| F-11 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Convertible Securities and Derivative Instruments
The Company evaluates its convertible debt instruments, preferred stock, warrants, options, and other equity-linked financial instruments to determine their appropriate classification and accounting treatment under applicable U.S. GAAP, including ASC Topics 480 and 815 and the relevant provisions of ASC Topic 470. This evaluation includes consideration of whether an instrument or embedded contractual feature requires liability classification, bifurcation, or separate measurement at fair value. Instruments or features classified as derivative liabilities are initially recognized at fair value and subsequently remeasured at each applicable reporting date, with changes in fair value recognized in earnings unless otherwise required by U.S. GAAP. Instruments classified within permanent or temporary equity are accounted for in accordance with the applicable recognition, measurement, and presentation requirements. The Company evaluates modifications, conversions, extinguishments, and cancellations of financial instruments based on the substance and contractual terms of each transaction.
Intangible Assets and Impairment
The Company evaluates its intangible assets, intellectual property interests, licensing rights, and other long-lived assets under the applicable provisions of ASC Topic 350, Intangibles—Goodwill and Other, and ASC Topic 360, Property, Plant, and Equipment. Finite-lived intangible assets are amortized over their estimated useful lives when applicable. Long-lived assets subject to amortization are reviewed for impairment when events or changes in circumstances indicate that their carrying amounts may not be recoverable. Recoverability is generally assessed by comparing the carrying amount of the applicable asset or asset group with the undiscounted future cash flows expected to result from its use and eventual disposition. If the carrying amount is not recoverable, an impairment loss is measured in accordance with the applicable accounting guidance. The Company also considers whether contractual rights have expired, been terminated, become unenforceable, or otherwise experienced changes affecting their recognition, measurement, or recoverability.
Stock-Based Compensation and Equity Instruments Issued for Services
The Company accounts for share-based payment arrangements under ASC Topic 718, Compensation—Stock Compensation, including applicable arrangements with employees and nonemployees. The cost of equity-classified share-based awards is generally measured based on grant-date fair value and recognized over the period in which the related services are provided or the applicable vesting conditions are satisfied. Liability-classified awards are measured and remeasured in accordance with the applicable provisions of ASC 718. Equity instruments issued in settlement of accrued compensation, accounts payable, or other obligations are evaluated based upon the substance of the underlying arrangement and the accounting guidance applicable to the original obligation and settlement transaction.
Related-Party Transactions
The Company identifies and evaluates related-party relationships and transactions in accordance with ASC Topic 850, Related Party Disclosures, and other applicable accounting guidance. Related parties may include principal shareholders, directors, executive officers, entities under common control, and other persons or entities capable of exercising significant influence over the Company’s financial or operating decisions. Transactions with related parties are recognized and measured under the applicable accounting guidance and disclosed when required, including the nature of the relationship, a description of the transaction, the amounts involved, and outstanding balances or commitments. Debt cancellations, contributions, settlements, and other transactions involving shareholders or entities under common control are evaluated to determine whether their economic substance requires recognition in earnings, equity, or another financial statement classification.
| F-12 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Revenue Recognition
The Company recognizes revenue from contracts with customers in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when control of promised goods or services is transferred to a customer in an amount reflecting the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company applies the five-step revenue recognition model by identifying the contract with the customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue as the applicable obligations are satisfied. Revenue from product sales is generally recognized when control of the products transfers to the customer. Revenue arising from licensing arrangements, if any, is evaluated based on the nature of the intellectual property rights granted, the contractual performance obligations, and the applicable recognition requirements of ASC 606. The Company separately evaluates whether amounts arising from arrangements outside the scope of ASC 606 should be recognized under other applicable accounting guidance.
Advertising and Promotional Expenses
Advertising and promotional expenditures are generally expensed as incurred, except when a different accounting treatment is required under applicable U.S. GAAP.
Income Taxes
The Company accounts for income taxes under ASC Topic 740, Income Taxes, using the asset and liability method. Deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, as well as operating loss and tax credit carryforwards, as applicable. Deferred tax assets are reduced by a valuation allowance when, based on the available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company recognizes the financial statement effects of uncertain tax positions when the applicable recognition and measurement criteria under ASC 740 are satisfied. Income tax expense or benefit for interim periods is determined in accordance with the applicable interim reporting provisions of ASC 740, including the estimated annual effective tax rate methodology and the separate recognition of discrete items when required.
Net Income (Loss) Per Common Share
The Company calculates basic and diluted net income (loss) per common share in accordance with ASC Topic 260, Earnings Per Share. Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of common shares outstanding during the applicable period.
Diluted net income (loss) per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were converted, exercised, or otherwise settled in common shares, to the extent their inclusion would be dilutive. Potentially dilutive instruments may include convertible preferred stock, convertible debt, warrants, options, and other equity-linked securities. The Company evaluates the applicable conversion provisions, participating rights, contractual limitations, and effective dates of outstanding instruments in determining the appropriate basic and diluted earnings-per-share calculations. Potential common shares are excluded from diluted earnings per share when their inclusion would be antidilutive.
| F-13 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recently Adopted and Issued Accounting Standards
The Company evaluates accounting standards updates issued by the Financial Accounting Standards Board to determine their applicability and potential effects on the Company’s consolidated financial statements. Accounting standards that became effective in prior reporting periods are reflected in the Company’s accounting policies to the extent applicable. The Company will disclose newly adopted accounting standards and recently issued standards not yet effective when their adoption has had, or is reasonably expected to have, a material effect on its financial position, results of operations, cash flows, or related disclosures.
NOTE B - GOING CONCERN
The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.
In accordance with Accounting Standards Codification (“ASC”) Topic 205-40, *Presentation of Financial Statements—Going Concern*, management evaluates whether conditions and events, considered in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued.
The Company has historically experienced operating losses, negative cash flows from operations, limited liquidity, and a working capital deficiency. These conditions, together with the Company’s continuing operating expenses, outstanding obligations, and anticipated funding requirements, raise substantial doubt about its ability to continue as a going concern.
Management’s plans include seeking additional financing, evaluating strategic transactions, reducing or restructuring outstanding obligations where appropriate, and pursuing opportunities to develop or realize value from the Company’s existing intellectual property and licensing arrangements.
The Company’s ability to execute these plans depends upon factors that include the availability of financing, creditor cooperation, the performance of third parties, and general business and market conditions. Management cannot assure that sufficient funding will be available or that the Company’s plans will be successfully implemented.
After considering management’s plans and the uncertainties associated with their implementation, management has concluded that substantial doubt about the Company’s ability to continue as a going concern has not been alleviated and continues to exist for the one-year period following the issuance date of these financial statements.
The accompanying unaudited condensed consolidated financial statements do not include adjustments that might result from the outcome of this uncertainty.
NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT
On
January 30, 2020, the Company entered into a Right of First Refusal Agreement with Kol Tuv Ventures, LLC (“KTV”), an entity
engaged in the cosmetics, health, and wellness industries. Under the agreement, the Company paid KTV $
| F-14 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE D - LOANS PAYABLE TO RELATED PARTIES
The Company has historically received financing from certain shareholders, officers, and other related parties to support its operations. Loans payable to related parties consisted of the following:
SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES
| September 30, 2026 | December 31, 2025 | |||||||
| 02490585 Ontario Inc. (Elisha Kalfa) and Yonah Kalfa, former holders of a total of | $ | – | $ | |||||
| Sigalush Ventures LLC (David Sencianes) and Fernando Bisker, former holders of a total of | – | |||||||
| Aitan Zacharin, former Chief Executive Officer | – | |||||||
| Porfirio Sanchez Talavera, Chairman | – | |||||||
| Total | $ | $ | ||||||
The
loans outstanding at December 31, 2025 originated under arrangements entered into in connection with the Company’s July 31, 2018
share exchange and related transactions. Under the reported terms of the applicable agreements, the loans were non-interest-bearing and
contemplated repayment following specified financing or revenue events, subject to additional maturity and conversion provisions. In
connection with the Company’s change of control, the Company entered into Debt Cancellation and Release Agreements, effective June
30, 2026, with (i) 02490585 Ontario Inc. (Elisha Kalfa) and Yonah Kalfa, and (ii) Sigalush Ventures LLC (David Sencianes) and Fernando
Bisker, under which the holders irrevocably canceled, released, and discharged loans of $
During
the nine months ended September 30, 2026, Porfirio Sanchez Talavera, the Company’s Chairman and, until September 18, 2026, its
Chief Executive Officer, made payments on behalf of the Company to fund its operating expenses. These amounts are non-interest-bearing
and have no stated maturity. As of September 30, 2026, loans payable to related parties totaled $
NOTE E - NOTES PAYABLE TO THIRD PARTIES
The Company had no notes payable to third parties outstanding at September 30, 2026 or December 31, 2025.
NOTE F - DERIVATIVE LIABILITIES
The Company has historically issued convertible promissory notes and other equity-linked instruments containing conversion or exercise provisions that required evaluation under Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging. In connection with its historical financing arrangements with FirstFire Global Opportunities Fund, LLC (“FirstFire”), the Company previously recognized derivative liabilities associated with certain conversion features of its convertible promissory notes. As previously reported, the derivative liability associated with these instruments was reduced to zero during 2021 following changes to the applicable conversion provisions. The FirstFire convertible promissory note was subsequently fully satisfied and extinguished pursuant to the June 12, 2025 amendment and modification agreement and the completion of the Company’s October 16, 2025 reverse stock split, as described in Note E. The Company reported no derivative liabilities as of December 31, 2025 or September 30, 2026.
| F-15 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE G — CAPITAL STOCK AND WARRANTS
Authorized Capital Stock
The
Company’s capital structure consists of common stock and preferred stock, each having a par value of $
Series A Convertible Preferred Stock
On
July 31, 2018, the Company issued
Series B Convertible Preferred Stock
On
October 22, 2025, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Department of State establishing
a series of
On
June 29, 2026, Trafalgar Asset Management, LLC acquired all
As of September 30, 2026, Trafalgar Asset Management, LLC held all outstanding Series B Preferred Shares. Under the Series B designation then in effect, the transfer of these shares was subject to provisions affecting the continuation of the enhanced voting rights originally associated with the Series B Preferred Stock. The voting rights applicable following the transfer are determined in accordance with those provisions, including the designation’s requirements concerning voting on an as-converted basis following specified transfers.
The Series B Preferred Shares do not provide for ordinary dividends and carry the liquidation rights established in the applicable designation. Subsequent amendments to the rights and preferences of the Company’s preferred securities are addressed in Note K, Subsequent Events.
| F-16 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE G — CAPITAL STOCK AND WARRANTS (continued)
Common Stock
The
Company’s common stock has a par value of $
Effective
October 16, 2025, the Company implemented a
Effective
September 17, 2026, the Company implemented a
In October 2025, the Company also reported the issuance of 44,679 shares of common stock in connection with a historical conversion of indebtedness owed to FirstFire.
During
the second quarter of 2026, the Company issued
As
of September 30, 2026, the Company reported
Change of Control
On June 29, 2026, Trafalgar Asset Management, LLC, an entity owned and controlled by Porfirio Sanchez Talavera, acquired the outstanding Series A Preferred Stock and Series B Preferred Stock pursuant to privately negotiated transactions. The acquisition of the preferred securities resulted in a change in the Company’s controlling shareholder and was accompanied by changes in executive management and the Board of Directors. The voting and conversion rights associated with the transferred preferred securities remained governed by the applicable designations in effect at the time of the transactions, including any transfer-related limitations. Subsequent amendments to the Company’s capital structure and preferred-stock rights are described in Note K, Subsequent Events.
Warrants
In
March 2021, in connection with its FirstFire financing, the Company issued three warrants designated Warrant A, Warrant B, and Warrant
C. The warrants originally entitled FirstFire to purchase an aggregate of
As of September 30, 2026, the Company had no outstanding warrants.
NOTE H - INCOME TAXES
The Company accounts for income taxes in accordance with Accounting Standards Codification (“ASC”) Topic 740, Income Taxes. The Company and its United States subsidiaries file federal income tax returns, and its Canadian subsidiary, Green C Corporation, has historically been subject to applicable Canadian federal and Ontario provincial income tax reporting requirements.
| F-17 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE H - INCOME TAXES (continued)
The Company has incurred cumulative operating losses and has historically generated net operating loss carryforwards that may be available to offset future taxable income, subject to applicable statutory limitations.
Deferred income tax assets are recognized for deductible temporary differences and available tax loss carryforwards. The Company maintains a valuation allowance against deferred tax assets to the extent management determines that realization of the associated tax benefits is not more likely than not.
Based upon the Company’s historical operating results, cumulative losses, limited revenue-generating activities, and uncertainty concerning future taxable income, the Company has historically maintained a full valuation allowance against its deferred tax assets.
The Company’s ability to utilize its federal net operating loss carryforwards and certain other tax attributes may be subject to limitations under Sections 382 and 383 of the Internal Revenue Code. These provisions generally restrict the utilization of certain tax attributes following specified changes in corporate ownership. The Company’s June 2026 change-of-control transactions, together with other historical changes in equity ownership, may result in limitations on the utilization of its existing tax attributes. Accordingly, the existence of net operating loss carryforwards does not assure that such amounts will be available to offset future taxable income.
The Company evaluates uncertain tax positions in accordance with ASC 740 and recognizes tax benefits only when the applicable recognition and measurement requirements are satisfied.
The Company’s tax returns remain subject to examination by applicable taxing authorities for the periods permitted under relevant statutes of limitation, including periods for which net operating loss carryforwards may be examined in connection with their utilization.
NOTE I - COMMITMENTS AND CONTINGENCIES
Pharmedica Exclusive License Agreement
On
June 21, 2018, Green C Corporation entered into an exclusive license agreement with Pharmedica Ltd. (“Pharmedica”), an Israeli
company, relating to certain intellectual property associated with transmucosal delivery technology for medicinal and recreational cannabis
products. The agreement required an initial license payment of $
Symtomax Sub-License Agreement
On
July 15, 2019, the Company entered into a sublicense agreement with Symtomax Unipessoal Lda (“Symtomax”), granting certain
nonexclusive rights to use Company technology and intellectual property for the development and commercialization of products in Europe,
the Middle East, and Africa. The agreement contemplated royalty payments to the Company ranging from
| F-18 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE I - COMMITMENTS AND CONTINGENCIES (continued)
Shaare Zedek Licensing and Development Arrangements
On October 19, 2021, the Company entered into a licensing agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer organization associated with Shaare Zedek Medical Center in Jerusalem, Israel, relating to certain cannabinoid-based therapeutic technologies. The Company also entered into associated research and development arrangements concerning the continued development and potential clinical evaluation of the licensed technology.
Under
the reported terms of the licensing agreement, annual licensing payments commence at $
The
agreement further provides for royalties based upon specified levels of net sales of qualifying products and a sublicense royalty of
The Company previously reported that certain annual licensing payments were placed on hold while specialized ingredients necessary for clinical development were being sourced. The timing and amount of future payments under
the arrangement depend upon the continuing contractual obligations, applicable development milestones, and any modifications or accommodations agreed upon by the parties.
The Company has not generated material commercial revenue from the licensed technology. Continued development and potential commercialization will require additional funding and remain subject to scientific, regulatory, contractual, and operational uncertainties.
Employment and Compensation Arrangements
The Company has historically entered into employment, consulting, and other service arrangements with executive officers and other service providers. Certain historical compensation obligations were settled through the issuance of equity securities or were canceled or released in connection with the Company’s June 2026 restructuring and change-of-control transactions. The Company recognizes compensation expense and related liabilities in accordance with the applicable terms of its service arrangements and U.S. GAAP.
On
July 31, 2018, the Company entered into a Services Agreement with Aitan Zacharin, its then Chief Executive Officer, providing for a monthly
base salary of $
| F-19 |
TRAFALGAR INTERNATIONAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Nine months ended September 30, 2026 and 2025
(Unaudited)
NOTE I - COMMITMENTS AND CONTINGENCIES (continued)
Other Commitments and Contingencies
The Company evaluates contractual commitments, threatened or pending claims, and other contingencies in accordance with ASC Topic 450, Contingencies, and other applicable accounting guidance. Loss contingencies are accrued when a loss is probable and reasonably estimable. Material contingencies that do not meet the criteria for accrual are disclosed when required under U.S. GAAP. The Company’s material historical licensing arrangements and related contractual commitments are described above and, where applicable, in Note A, Nature of Operations and Summary of Significant Accounting Policies.
NOTE J-RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
The
Company previously restated its consolidated financial statements for the three months ended March 31, 2025, originally included in its
Quarterly Report on Form 10-Q filed on May 12, 2025, to correct the accounting treatment of certain obligations arising under its convertible
promissory note with FirstFire Global Opportunities Fund, LLC (“FirstFire”). The restatement included recognition of additional
default interest and penalties totaling $
NOTE K – SUBSEQUENT EVENTS
The Company has evaluated subsequent events occurring after September 30, 2026, through the date these unaudited condensed consolidated financial statements were issued.
Trading Symbol Change
On October 21, 2026, following processing by FINRA, the Company’s common stock began trading under the symbol “TRFA,” replacing the temporary symbol “GCAND” under which the common stock traded following the Second Reverse Split described in Note A.
Amendment and Restatement of Articles of Incorporation
On October 12, 2026, the Company’s Board of Directors approved an amendment and restatement of the Company’s Articles of Incorporation to revise its authorized capital structure and the rights, preferences, privileges, and limitations of its preferred securities. The amendment and restatement was also approved by the shareholders entitled to vote thereon.
The
Amended and Restated Articles authorize
Preferred
Stock is nonparticipating with respect to dividends and carries a liquidation preference of $
Because the Amended and Restated Articles became effective subsequent to September 30, 2026, the Company’s capital structure and the rights of its outstanding securities as of September 30, 2026, are presented in accordance with the governing instruments then in effect.
| F-20 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the financial condition and results of operations of Trafalgar International, Inc. (formerly The Greater Cannabis Company, Inc.) (the “Company,” “Trafalgar,” “we,” “us,” or “our”) should be read in conjunction with the unaudited condensed consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report on Form 10-Q, as well as the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. This discussion contains forward-looking statements involving risks and uncertainties. Actual results may differ materially from those expressed or implied by such statements as a result of numerous factors, including the Company’s ability to obtain financing, execute its business strategy, complete potential acquisitions and strategic transactions, and maintain sufficient liquidity to fund its operations.
Company Overview and Business Transition
Trafalgar International, Inc. is a Florida corporation that historically operated under the name The Greater Cannabis Company, Inc. The Company has pursued business opportunities involving the development, licensing, and commercialization of cannabinoid-based technologies and related intellectual property.
From July 2018 through mid-2021, the Company’s principal business activities focused on developing and commercializing proprietary and licensed technologies for the transmucosal and transdermal delivery of cannabinoids. These activities included the development of an oral transmucosal patch platform intended to facilitate the absorption of active compounds through the buccal mucosa.
Although the Company achieved limited initial commercialization of this technology, historical management subsequently redirected its development activities toward other opportunities in the cannabinoid therapeutics sector.
On October 19, 2021, the Company entered into a licensing arrangement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer organization associated with Shaare Zedek Medical Center in Jerusalem, Israel. The arrangement concerned certain cannabinoid-based therapeutic technologies being investigated for potential applications in neuropsychiatric and neurological disorders.
The licensed technology originated from research involving cannabinoid formulations and their potential therapeutic applications. The Company’s historical development strategy contemplated further research, clinical evaluation, and potential commercialization of the licensed technology, subject to applicable regulatory requirements, financing, and successful completion of development activities.
The Company has not generated material commercial revenues from these arrangements. The development and commercialization of cannabinoid-based therapeutic products remain subject to substantial scientific, regulatory, financial, and operational uncertainties.
June 2026 Change of Control and Business Transition
On June 29, 2026, the Company completed a series of transactions involving the acquisition of its outstanding preferred securities by Trafalgar Asset Management, LLC, a Delaware limited liability company owned and controlled by Porfirio Sanchez Talavera. The transactions resulted in a change in the Company’s principal shareholder and were accompanied by changes in management, corporate governance, and the Company’s strategic direction.
In connection with the change of control, the Company also entered into agreements providing for the cancellation, release, or extinguishment of certain historical indebtedness and other obligations. These transactions materially reduced the Company’s previously reported liabilities.
Following the change of control, the Company appointed a new executive management team, including Carlos Septién Michel, who was appointed Chief Operating Officer on July 29, 2026 and Chief Executive Officer effective September 18, 2026, Michelle Cervantes Vivanco as Chief Financial Officer, and Ernesto Gómez Berjón as Chief Growth Officer, with Porfirio Sanchez Talavera serving as Chairman of the Board. The new management team commenced evaluating the Company’s historical obligations, existing intellectual property interests, capitalization, and potential strategic opportunities as part of the transition to its revised business strategy.
| 1 |
On July 29, 2026, the Company filed Articles of Amendment with the Florida Department of State changing its name to Trafalgar International, Inc. and effecting a 1-for-5 reverse split of its common stock. The name change and reverse split became effective in the market on September 17, 2026, and the common stock began trading under the symbol “TRFA” on October 21, 2026. On October 12, 2026, the Company’s Board of Directors and majority shareholders approved the amendment and restatement of the Company’s Articles of Incorporation, which will become effective upon filing with the Florida Department of State, as described in Note K to the consolidated financial statements.
The Company intends to pursue this strategy through potential acquisitions, direct investments, joint ventures, licensing arrangements, strategic partnerships, and other business development opportunities.
Management’s objective is to identify transactions and operating opportunities that may provide a foundation for future revenue generation, business expansion, and long-term shareholder value.
The Company has not established a history of operating revenues under its revised business strategy. Its ability to implement that strategy will depend upon obtaining financing, identifying suitable opportunities, negotiating acceptable transaction terms, and successfully integrating or developing acquired businesses or assets.
The Company may also evaluate opportunities to retain, license, monetize, or otherwise realize value from its existing intellectual property portfolio.
Additional information concerning the Company’s historical operations, intellectual property arrangements, change of control, and capital structure is included in the notes to the accompanying consolidated financial statements.
Results of Operations
Comparison of the Three and Nine Months Ended September 30, 2026 and 2025.
Revenue
The Company reported no revenue during the three and nine months ended September 30, 2026 and 2025.
The absence of revenue reflects the Company’s limited commercialization activities and the transition of its business strategy following the June 2026 change of control.
Management expects that the timing and amount of future revenues, if any, will depend upon the successful implementation of the Company’s revised business strategy and the development or acquisition of revenue-producing operations.
Operating Expenses
Operating expenses for the three months ended September 30, 2026 were $90,335, compared with $37,412 for the corresponding period in 2025. Operating expenses for the nine months ended September 30, 2026 were $135,266, compared with $129,199 for the corresponding period in 2025, representing an increase of $6,067, or approximately 4.7%.
Historically, the Company’s operating expenses have consisted primarily of executive compensation, professional fees, administrative expenses, research and development expenditures, and other costs associated with maintaining its corporate operations and public reporting obligations.
| 2 |
The increase in operating expenses for both periods resulted primarily from professional services of $65,510 incurred during the third quarter of 2026, compared with no professional services in the corresponding periods of 2025. This increase was partially offset by lower officers’ compensation, which was $0 and $30,000 for the three months ended September 30, 2026 and 2025, respectively, and $30,000 and $90,000 for the nine months ended September 30, 2026 and 2025, respectively, following the resignation of the Company’s former Chief Executive Officer in connection with the change of control.
As the Company implements its revised business strategy, operating expenses may increase as a result of additional personnel, professional services, due diligence activities, transaction expenses, and costs associated with the development or acquisition of operating businesses.
Other Income and Expenses
The Company’s other income and expenses during the nine months ended September 30, 2026 were $622,933, compared with other expenses of $540,170 for the corresponding period in 2025. Other income for the 2026 period consisted of a gain on cancellation of debt of $621,450 and a gain on cancellation of Series A Preferred Stock of $1,483, and was materially affected by transactions involving the cancellation, settlement, and extinguishment of historical obligations in connection with the Company’s restructuring and June 2026 change of control.
In connection with these transactions, the Company entered into agreements providing for the cancellation and release of certain historical indebtedness and other obligations. These arrangements included obligations arising from prior financing transactions and related-party arrangements, as further described in the accompanying notes to the consolidated financial statements.
The financial effects of these transactions are reflected in the Company’s consolidated financial statements in accordance with applicable accounting principles, including the recognition and classification of extinguishment gains and equity-related adjustments, as appropriate.
The cancellation and settlement of historical obligations were nonrecurring in nature and did not generate operating cash inflows. Accordingly, management does not consider the financial statement effects of these transactions indicative of the Company’s ability to generate recurring operating revenue or sustainable operating earnings.
The Company’s future other income and expenses will depend upon its financing arrangements, capital structure, investment activities, and other transactions undertaken in connection with its revised business strategy.
Net Income (Loss)
For the three months ended September 30, 2026, the Company reported a net loss of $90,335, compared with a net loss of $36,099 for the corresponding period in 2025. For the nine months ended September 30, 2026, the Company reported net income of $487,667, compared with a net loss of $669,369 for the corresponding period in 2025.
The improvement in net results was primarily attributable to the recognition of nonrecurring income associated with the extinguishment of historical liabilities.
The Company’s reported net income did not result from revenue-generating operations and does not, by itself, indicate that the Company has achieved operating profitability or positive operating cash flow.
Management anticipates that future operating results will depend substantially upon the Company’s ability to secure additional capital and execute its revised business strategy.
| 3 |
Liquidity and Capital Resources
Financial Condition
As of September 30, 2026, the Company reported cash of $111, compared with $815 as of December 31, 2025.
The Company has historically financed its operations through related-party advances, debt financing, and the issuance of equity securities rather than cash generated from operating activities.
During 2026, the Company completed transactions resulting in the cancellation or extinguishment of certain historical liabilities, including related-party loans and third-party debt obligations.
Related-party loans payable decreased from $263,600 at December 31, 2025 to $85,624 at September 30, 2026. The related-party loans outstanding at December 31, 2025 were extinguished in connection with the change of control, and the balance at September 30, 2026 consists of loans made by Porfirio Sanchez Talavera during 2026 to fund the Company’s operating expenses.
Although the cancellation of historical obligations improved the Company’s reported financial position, the transactions did not generate operating cash or provide a continuing source of liquidity.
The Company continues to have limited cash resources and expects to require additional financing to fund its ongoing operations, satisfy current obligations, maintain its public company reporting requirements, and implement its business strategy.
Cash Flows
The following table summarizes the Company’s cash flows for the nine months ended September 30, 2026 and 2025:
| 2026 | 2025 | |||||||
| Net cash used in operating activities | $ | (96,828 | ) | $ | (36,013 | ) | ||
| Net cash used in investing activities | — | — | ||||||
| Net cash provided by financing activities | $ | 96,124 | — | |||||
| Net decrease in cash | $ | (704 | ) | $ | (36,013 | ) | ||
Operating Activities
Net cash used in operating activities was $96,828 for the nine months ended September 30, 2026, compared with $36,013 for the corresponding period in 2025.
The increase in operating cash usage primarily reflects payment of professional services and other operating expenses during the 2026 period.
The Company’s operating activities have not generated sufficient cash to support its continuing obligations.
Investing Activities
The Company reported no material cash flows from investing activities during the nine months ended September 30, 2026 or 2025.
Future investing activities may include expenditures associated with acquisitions, strategic investments, technology development, and other business opportunities, depending upon the availability of financing.
| 4 |
Financing Activities
Net cash provided by financing activities was $96,124 for the nine months ended September 30, 2026, consisting of loans from Porfirio Sanchez Talavera, compared with no financing cash inflows during the corresponding period in 2025.
The Company expects that financing activities will remain an important source of liquidity until it establishes operations capable of generating sufficient positive cash flow.
Capital Requirements and Going Concern
The Company has limited liquidity, no established source of recurring operating revenue, and continuing cash requirements.
Management intends to seek additional capital through private placements of debt or equity securities, strategic investments, financing arrangements, and other transactions that may be available.
There can be no assurance that the Company will obtain sufficient financing, that financing will be available on commercially acceptable terms, or that management will successfully implement its business strategy.
Additional equity financing could result in substantial dilution to existing shareholders. Debt financing could impose additional payment obligations, restrictive covenants, or security interests in Company assets.
The Company’s ability to continue as a going concern depends upon obtaining adequate financing and ultimately establishing sustainable operations.
Management has determined that substantial doubt exists regarding the Company’s ability to continue as a going concern for one year following the issuance of the accompanying financial statements. See Note B to the consolidated financial statements.
Critical Accounting Policies and Estimates
The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.
Preparation of these financial statements requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures.
Management considers accounting policies and estimates critical when they involve significant judgment or uncertainty and could materially affect the Company’s reported financial condition or results of operations.
Debt Extinguishments and Related-Party Transactions
The Company evaluates the cancellation, settlement, or extinguishment of financial obligations under the applicable provisions of U.S. GAAP.
The accounting treatment of debt extinguishments depends upon the contractual terms of the applicable obligations, the nature of the settlement, the consideration exchanged, and the relationship between the Company and the creditor.
Transactions involving shareholders or related parties may require different accounting treatment from settlements with unrelated creditors.
These judgments are particularly significant in evaluating the Company’s 2026 restructuring transactions.
| 5 |
Equity Instruments and Share-Based Compensation
The Company accounts for equity instruments issued in exchange for employee and nonemployee services in accordance with ASC Topic 718, Compensation—Stock Compensation.
Determining the appropriate recognition and measurement of share-based compensation may require management to evaluate the fair value of the securities issued, the terms of the applicable arrangements, and the period over which services are rendered.
Income Taxes
The Company accounts for income taxes under ASC Topic 740, Income Taxes.
Management evaluates the realizability of deferred tax assets, including net operating loss carryforwards, based upon available evidence concerning future taxable income and applicable statutory limitations.
The Company’s historical losses and changes in ownership are significant considerations in evaluating its deferred tax assets and related valuation allowances.
Intangible Assets and Impairment
The Company evaluates intangible assets and other long-lived assets for impairment in accordance with applicable accounting guidance.
These evaluations may require judgments regarding the commercial viability of licensed technologies, expected future cash flows, development requirements, and other factors affecting the recoverability of carrying values.
Actual results may differ materially from management’s estimates and assumptions.
Off-Balance Sheet Arrangements
The Company has not entered into off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on its financial condition, results of operations, liquidity, capital expenditures, or capital resources.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, and is not required to provide the information otherwise required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company’s management, with the participation and supervision of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of September 30, 2026, pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to provide reasonable assurance that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.
| 6 |
Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures.
Based upon this evaluation, management concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2026.
The determination reflects material weaknesses in the Company’s internal control environment, including limitations associated with its historical organizational structure, limited accounting and financial reporting resources, and insufficient segregation of duties.
The Company previously disclosed material weaknesses in its internal control over financial reporting in its Annual Report on Form 10-K for the year ended December 31, 2025. Management continues to evaluate these weaknesses and the measures necessary to improve the Company’s disclosure controls and financial reporting processes.
Remediation of Material Weaknesses
Following the Company’s June 2026 change of control and subsequent management transition, management commenced a review of the Company’s existing accounting, financial reporting, and disclosure procedures to identify deficiencies and evaluate appropriate corrective measures.
Management’s remediation objectives include strengthening oversight of financial reporting, improving documentation and review procedures, enhancing segregation of duties where practicable, and utilizing qualified accounting and financial reporting professionals to support the preparation and review of the Company’s periodic reports.
The Company’s ability to implement these measures depends upon its available financial and personnel resources. Management has not concluded that the previously identified material weaknesses have been fully remediated.
Management will continue to evaluate the effectiveness of its disclosure controls and procedures and internal control over financial reporting. Until sufficient corrective measures have been implemented and their effectiveness demonstrated, the identified material weaknesses may continue to adversely affect the Company’s financial reporting processes.
Changes in Internal Control Over Financial Reporting
During the quarter ended September 30, 2026, there were no changes in the Company’s internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act, that materially affected, or were reasonably likely to materially affect, the Company’s internal control over financial reporting.
| 7 |
PART II- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
There are no material pending legal proceedings to which the Company or any of its subsidiaries is a party or to which any of their respective properties is subject that are required to be disclosed pursuant to Item 103 of Regulation S-K.
ITEM 1A. RISK FACTORS
The Company is a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, and is not required to provide the information otherwise required by this Item.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The Company did not sell any equity securities during the three months ended September 30, 2026 that were not registered under the Securities Act of 1933, as amended, and that have not otherwise been reported in a Current Report on Form 8-K or another report filed with the Securities and Exchange Commission.
The Company did not repurchase any of its equity securities during the three months ended September 30, 2026.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During
the three months ended September 30, 2026, no director or officer of the Company
ITEM 6. EXHIBITS
| Exhibit No. | Description | |
| 31.1 | Certification of Carlos Septién Michel, Chief Executive Officer (Principal Executive Officer), pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended (filed herewith). | |
| 31.2 | Certification of Michelle Cervantes Vivanco, Chief Financial Officer (Principal Financial Officer), pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended (filed herewith). | |
| 32.1 | Joint Certification of Carlos Septién Michel, Chief Executive Officer (Principal Executive Officer), and Michelle Cervantes Vivanco, Chief Financial Officer (Principal Financial Officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 8 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRAFALGAR INTERNATIONAL, INC. | |
| November 19, 2026 | /s/ Carlos Septién Michel |
| Chief Executive Officer | |
| (Principal executive officer) |
| 9 |